Skip to main
SNN
SNN logo

SNN Stock Forecast & Price Target

SNN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Smith & Nephew experienced underlying revenue growth of 5.3%, with significant contributions from its orthopedic and sports medicine segments, showcasing a robust demand particularly in the US market. The company anticipates stronger performance in the second half of the year, underpinned by operational improvements and increased adoption of its advanced technologies, such as the CORI system, which has reached over 1,000 placements. Projections for 2025 indicate continued growth, with guidance of 5% growth and a trading profit margin expected between 19.0% and 20.0%, reinforcing a positive outlook for the firm's financial performance.

Bears say

Smith & Nephew is projecting a weaker financial performance in FY25, particularly in Q1, influenced by a combination of fewer selling days, ongoing inventory challenges in China, and the impacts of evolving reimbursement rates in the US healthcare system. The company's return on invested capital (ROIC) for its orthopedic segment remains significantly below that of its sports medicine and advanced wound management counterparts, highlighting operational inefficiencies within its largest revenue-generating segment. Additionally, persistent headwinds in China and broader market risks tied to political stability and regulatory changes could further exacerbate revenue challenges, contributing to a negative outlook.

SNN has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Smith & Nephew (SNN) Forecast

Analysts have given SNN a Hold based on their latest research and market trends.

According to 4 analysts, SNN has a Hold consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Smith & Nephew (SNN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.